Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colchicine plus prednisone versus standard treatment for moderate to severe COVID-19 in frail older inpatients
2020-002462-14Phase 2Terminated
- Sponsor
- Fundació Clínic per a la Recerca Biomèdica
- Start
- Jun 2020
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of colchicine and prednisone in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Fundació Clínic per a la Recerca Biomèdica. Started Jun 2020; status: terminated.
02
Drugs
colchicineprednisone
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-002462-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002462-14.